Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration.

Nature neuroscience·2026
Same author

Characterization of vascular tortuosity throughout the murine oxygen-induced retinopathy model of ischemic retinopathy.

JCI insight·2026
Same author

Neuroprotective strategies for retinal disease.

Handbook of clinical neurology·2026
Same author

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration.

Acta ophthalmologica·2026
Same author

Genomic characterization of sub-populations in human pluripotent stem cell-derived retinal progenitor cells driving retinal lamination.

Stem cell reports·2026
Same author

Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2.

Ophthalmology science·2026

Related Experiment Video

Updated: Jul 17, 2026

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

Ocular neovascularization: basic mechanisms and therapeutic advances.

Michael Dorrell1, Hannele Uusitalo-Jarvinen, Edith Aguilar

  • 1Department of Cell Biology, The Scripps Research Institute, Department of Ophthalmology, Scripps Clinic, La Jolla, California 92014, USA.

Survey of Ophthalmology
|January 24, 2007
PubMed
Summary

Ocular neovascularization causes vision loss. This review covers new therapies for neovascular eye diseases, including pre-clinical and clinical trial results for angiogenesis inhibitors.

More Related Videos

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

Related Experiment Videos

Last Updated: Jul 17, 2026

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Background:

  • Ocular neovascularization is a primary cause of irreversible vision loss.
  • Abnormal angiogenesis leads to dysfunctional blood vessels, causing complications like hemorrhage and retinal detachment.
  • Understanding angiogenesis is crucial for developing effective treatments.

Purpose of the Study:

  • To review the clinical scope of neovascular eye diseases.
  • To discuss the principles of angiogenesis.
  • To highlight recent therapeutic advances for ocular neovascularization.

Main Methods:

  • Review of scientific literature on ocular neovascularization.
  • Analysis of pre-clinical research on angiogenesis inhibitors.
  • Summary of clinical trial outcomes for novel therapeutics.

Main Results:

  • Recent laboratory advances have yielded promising therapeutic compounds.
  • Several drugs are in pre-clinical development for treating neovascular eye conditions.
  • Clinical trials are evaluating the efficacy of these treatments for ocular neovascularization.

Conclusions:

  • Targeting angiogenesis offers a viable strategy for treating vision-threatening eye diseases.
  • Ongoing research and clinical trials are advancing therapeutic options.
  • New treatments hold potential to mitigate vision loss due to ocular neovascularization.